Articles: palliative-care.
-
Randomized Controlled Trial Clinical Trial
Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?
Current chemotherapy treatment of metastatic non-small cell lung cancer has demonstrated some objective responses, but is still largely palliative. This report reviews the results of a randomized trial in patients with advanced metastatic non-small cell lung cancer which compared treatment with supportive care (treatment with palliative radiation, psychosocial support, analgesics, nutritional support) to supportive care plus combination chemotherapy with cisplatin and vinblastine. ⋯ The authors conclude that contemporary combination chemotherapy provides only modest survival benefit to patients with advanced metastatic non-small cell lung cancer and should not be considered standard therapy. Future investigations of chemotherapy in patients with unresectable non-small cell lung cancer should continue to utilize control arms which provide high-quality supportive care.
-
Pain is a major symptom in more than two-thirds of patients with far-advanced cancer. Pain control is thus one of the most significant ways to enable terminally ill cancer patients to live full lives up until the moment of death. Analgesic drug therapy is the mainstay of cancer pain management. ⋯ For mild to moderate pain, a nonopioid analgesic such as nonsteroidal anti-inflammatory drug or acetaminophen should be prescribed for the patient. If and when this treatment no longer relieves the pain, the patient should receive a strong opioid such as morphine or buprenorphine, together with a co-analgesic, if appropriate. The patient must receive careful and frequent supervision to ensure that the treatment continues to match the pain effectively and to take precautionary measures against side effects.
-
Clinical Trial Controlled Clinical Trial
Treatment of severe cancer pain by low-dose continuous subcutaneous morphine.
In a prospective and intraindividually controlled trial, we have compared the efficacy and safety of a continuous subcutaneous morphine infusion with conventional intermittent oral or subcutaneous morphine application. Twenty-eight in-patients with cancer pain received a short-term infusion lasting 2-42 days, and 8 out-patients underwent long-term infusion from 49 to 197 days during the terminal stage of their disease. Continuous subcutaneous morphine infusion significantly (P less than 0.001) improved both pain and quality of life when compared to conventional morphine application. ⋯ Constipation occurred in 3 of the 36 patients and was always controlled by the addition of laxatives; no nausea, sedation or respiratory depression were observed. Signs of tolerance developed in 2 patients on long-term infusion, but the use of continuous subcutaneous methadone for 2 weeks reversed the tolerance. The study presented indicates that low-dose continuous subcutaneous morphine provides a valuable treatment modality for severe terminal cancer pain exhibiting a high degree of both efficacy and safety.
-
This study examines the nature, pattern, and consequences of pain experienced by cancer patients, both during hospitalization and during the immediate posthospitalization period. Of the 240 hospitalized cancer patients screened, 45% were found to be in pain. Although 59% of these patients had found ways to reduce their pain, nearly one third reported being seriously limited in their daily activities. ⋯ Applied pain management strategies were rated by two physicians as inadequate in 54% of cases. The most frequent recommendation for improved pain management was an increase in the dosage or a change in the class of analgesics. The importance of periodic assessment of pain and its consequences, both physical and psychological, is discussed in light of increasing the level of information available to physicians and patients regarding appropriate approaches to pain management.
-
Randomized Controlled Trial Clinical Trial
Central post-stroke pain--a controlled trial of amitriptyline and carbamazepine.
A double-blind, 3-phase, cross-over, placebo-controlled trial of the pain-relieving effect of amitriptyline and carbamazepine was carried out in 15 patients with central post-stroke pain (CPSP) but without signs of depression. Treatment was given, in randomized order, for periods of 4 weeks, separated by 1 week wash-out. The final doses were 75 and 800 mg/day, respectively, for amitriptyline and carbamazepine. ⋯ No final dose reduction was necessary. Carbamazepine caused more side effects and the final dose had to be reduced in 4 patients. However, only 1 patient had to be taken off medication, on day 25, due to drug interaction.